We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
AEterna Zentaris has initiated the first of three studies in its Phase III program in benign prostatic hyperplasia (BPH) with its luteinizing hormone-releasing hormone antagonist compound, cetrorelix.
ProEthic Pharmaceuticals has announced successful Phase III clinical trial results for PRO-513, its product candidate for the treatment of migraine headaches.
GlaxoSmithKline (GSK) announced it has received approval from Health Canada for use of its antiviral Relenza (zanamivir) dry powder for inhalation for the prevention of influenza in adults and children 7 years of age and older.
MedImmune announced that the FDA has approved the company's new refrigerated formulation of FluMist (influenza virus vaccine live, intranasal) for use in helping to prevent influenza in healthy children and adults from 5 years to 49 years of age.
Dynavax Technologies has announced that the analysis of interim one-year data from its two-year DARTT ragweed allergy trial indicated that no meaningful ragweed-specific allergic disease was observed in the study population, making it impossible to measure the therapeutic effect of Tolamba treatment.
BN ImmunoTherapeutics announced that the FDA has accepted its investigational new drug application for the company's breast cancer vaccine, MVA-BN-HER2.